Pyxis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYXS research report →
Range $6 – $7
Price Chart
About the company
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
- CEO
- Thomas Civik
- IPO
- 2021
- Employees
- 56
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on PYXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $197.67M
- P/E
- -2.21
- PEG
- -0.29
- P/S
- 17.91
- P/B
- 17.45
- EV/EBITDA
- -2.36
- Div Yield
- 0.00%
- Gross Margin
- 99.76%
- Op Margin
- -834.44%
- Net Margin
- -803.83%
- ROE
- -215.23%
- ROIC
- -314.66%
Latest fiscal year · YoY change
- Revenue
- $13.86M-14.2%
- Gross Profit
- $11.47M-26.8%
- Op Income
- $-84,420,000
- Net Income
- $-79,621,000-3.0%
- EPS
- $-1.28+3.0%
- OCF Growth
- -10.1%
- FCF Growth
- -9.7%
- 52W High
- $5.55
- 52W Low
- $1.03
- 50D MA
- $2.62
- 200D MA
- $2.33
- Beta
- 1.32
- RSI (14)
- 53
- Avg Volume
- 1.21M
No earnings-call transcripts are available for PYXS yet.
- Free Float
- 58.8%
- Shares Outstanding
- 63.36M
- Float Shares
- 37.25M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.34M | ▲ 171.81K |
| Cubist Systematic Strategies, LLC | 33.06K | ▲ 33.06K |
| Two Sigma Advisers, LP | 22.62K | ▼ 29.90K |
| Point72 Asia (Singapore) Pte. Ltd. | 18.06K | ▼ 1.17K |
| Cwm, LLC | 34 | ▲ 34 |
Held by 38 ETFs
Biggest fund positions in PYXS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 26 | Civik Thomas | other | 250,956 |
| Jun 30, 26 | GordonMD Global Investments LP | other | 0 |
| Jun 30, 26 | GordonMD Global Investments LP | other | 4,900,039 |
| Jun 30, 26 | Dupont Jakob | other | 35,000 |
| Jun 30, 26 | Dupont Jakob | other | 35,000 |
| Jun 30, 26 | Dupont Jakob | sell | 35,000 |
| Mar 24, 26 | Dupont Jakob | other | 45,867 |
| Mar 24, 26 | Wadhane Jitendra | other | 109,461 |
| Mar 24, 26 | Wadhane Jitendra | other | 262,635 |
| Mar 24, 26 | FLAVIN JOHN L | other | 45,867 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PYXS coverage
Recent articles, reports, and earnings notes.
No research on PYXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PYXS report →Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
globenewswire.com · Aug 13
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
defenseworld.net · Aug 13
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
globenewswire.com · Jun 30
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
globenewswire.com · May 14
Pyxis Oncology to Participate in Upcoming Investor Conferences
globenewswire.com · May 13
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
globenewswire.com · May 7
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
globenewswire.com · Apr 17
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com · Mar 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.